Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Zydol XL 400 mg prolonged-release Tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Tramadol hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Tramadol hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for These tablets have been prescribed for you to relieve moderate to severe pain over a period of 24 hours. They contain the active ingredient tramadol which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking Zydol XL tablets suddenly. Your prescriber should have explained how long you will be taking them for and when it is appropriate to stop, how to do this safely. These tablets are only for use in adults and adolescents over 12 years of age.

What you need to know before you take it

e Zydol XL tablets Do not take Zydol XL tablets:

  • if you are allergic to tramadol or any of the other ingredients of these tablets (listed in section 6 of this leaflet);
  • if you have drunk too much alcohol, or taken more than the recommended dose of sleeping tablets, painkillers or psychotropic medicines (used to treat psychiatric or mental disorders);
  • if you are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or if you have taken this type of medicine in the last two weeks;
  • to treat withdrawal symptoms that may occur when you stop taking another strong painkiller;
  • if you have a rare hereditary problem of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.

Warnings and precautions Talk to your prescriber before taking these tablets if you:

  • are or have ever been addicted to opioids, alcohol, prescription medicines or illegal drugs;
  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating when you have stopped taking alcohol or drugs;
  • feel you need to take more of this medicine to get the same level of pain relief. This may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever;
  • suffer from depression and you are taking antidepressants as some of them may interact with tramadol (see 'Other medicines and Zydol XL tablets).
  • suffer from, or have ever suffered from epilepsy, seizures, fits or convulsions;
  • know you are suffering from a brain injury or tumour, or you have a head injury, severe headache or feel sick, as this may indicate that the pressure in your skull is increased. This is because the tablets may make symptoms worse or hide the extent of any head injury;
  • have severe liver or kidney problems;
  • are suffering from shock (this may make you suddenly feel very lightheaded, faint, cold or clammy and look pale);
  • are feeling very lightheaded or faint;
  • have a condition where you breathe more slowly and weakly than usual (respiratory depression);
  • have a condition where your breathing stops for short periods whilst you are asleep, known as sleep apnoea;
  • are currently suffering from constipation If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital that you are taking these tablets. Your doctor may adjust your treatment. These tablets should not be used for short-term pain after an operation owing to the increased risk of dependence and breathlessness. Tolerance, dependence, and addiction This medicine contains tramadol which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Zydol XL can also lead to dependence, abuse and addiction, which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Zydol XL if:
  • You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction").
  • You are a smoker.
  • You have ever had problems with your mood (depression, anxiety, or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking Zydol XL, it could be a sign that you have become dependent or addicted:
  • You need to take the medicine for longer than advised by your doctor
  • You need to take more than the recommended dose
  • You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'
  • You have made repeated, unsuccessful attempts to quit or control the use of the medicine
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects') If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Zydol XL). Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. There is a small risk that you may experience a so-called serotonin syndrome that can occur after having taken tramadol in combination with certain antidepressants or tramadol alone. Seek medical advice immediately if you have any of the symptoms related to this serious syndrome (see section 4 'Possible side effects'). Sleep-related breathing disorders Zydol XL tablets can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Tramadol is transformed in the liver by an enzyme. Some people have a variation of this enzyme and this can affect people in different ways. In some people, they may not get enough pain relief but other people are more likely to get serious side effects. If you notice any of the following side effects, you must stop taking this medicine and seek immediate medical advice: slow or shallow breathing, confusion, sleepiness, small pupils, feeling or being sick, constipation, lack of appetite. Talk to your doctor, pharmacist or nurse if you experience any of the following symptoms while taking Zydol XL tablets: extreme fatigue, lack of appetite, severe abdominal pain, nausea, vomiting or low blood pressure. This may indicate that you have adrenal insufficiency (low cortisol levels). If you have these symptoms, contact your doctor, who will decide if you need to take hormone supplement. Children and adolescents Use in children after an operation

If your child is given these tablets after an operation they will be monitored closely to ensure that they are not breathing more slowly or weakly than usual (respiratory depression). If you notice that your child is breathing slowly or weakly after an operation, tell their doctor or nurse immediately. Use in children with breathing problems Tramadol is not recommended in children with breathing problems, since any side effects of tramadol may be worse in these children. Other medicines and Zydol XL tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Using Zydol XL tablets at the same time as other medicines that slow down the central nervous system can cause slow or difficulty breathing (respiratory depression), severe sleepiness, loss of consciousness and death. These medicines include:

  • other medicines used to treat pain known as opioids (such as codeine or morphine);
  • medicines used to treat anxiety;
  • medicines used to make you feel sleepy (such as benzodiazepines);
  • medicines used to treat psychiatric or mental disorders (such as phenothiazines);
  • medicines used to treat depression, including a type of medicine known as monoamine oxidase inhibitors (MAOIs), such as tranylcypromine, phenelzine and isocarboxazid. You should not use Zydol XL tablets if you are currently taking this type of medicine, or have taken this medicine in the last two weeks (see section 2 'Do not take…'). Because of this, your doctor will only prescribe Zydol XL tablets where there are no other treatment options, and only in small doses for short periods of time. If you or your friends, family or caregivers notice that you are having difficulty breathing or that you have become very sleepy or lost consciousness you (or they) should inform your doctor immediately. If you are taking any of the following, your risk of experiencing seizures, fits or convulsions may be increased whilst you are taking Zydol XL tablets:
  • medicines used to treat depression known as selective serotonin reuptake inhibitors, or SSRIs (such as citalopram, fluoxetine or sertraline);
  • medicines used to treat depression known as selective norepinephrine reuptake inhibitors, or SNRIs (such as venlafaxine or duloxetine);
  • tricyclic antidepressants (such as amitriptyline, clomipramine or imipramine);
  • monoamine oxidase inhibitors, or MAOIs (such as tranylcypromine, phenelzine or isocarboxazid);
  • medicines used to treat serious psychiatric disorders (antipsychotics);
  • a medicine used to help stop smoking known as bupropion;
  • a medicine used to treat depression, obsessive compulsive disorder and anxiety, known as mirtazapine;
  • tetrahydrocannabinol or THC (cannabis). The risk of side effects increases if you are taking certain antidepressants. Zydol XL tablets may interact with these medicines and you may experience serotonin syndrome (see section 4 'Possible side effects'). Tell your doctor or pharmacist if you are taking:
  • carbamazepine to treat seizures, fits or convulsions and certain pain conditions;
  • cimetidine, a medicine used to treat stomach ulcers;
  • ritonavir, a medicine used to treat HIV;

• • • • •

digoxin, a medicine used to treat heart failure or an irregular heart beat; other strong analgesics or 'painkillers' (such as buprenorphine, nalbuphine and pentazocine); gabapentin or pregabalin to treat epilepsy or pain due to nerve problems (neuropathic pain); certain medicines to prevent your blood clotting or to help thin your blood (known as coumarin anticoagulants, for example warfarin); ondansetron, a medicine used to treat nausea and vomiting.

Zydol XL tablets and alcohol Drinking alcohol whilst taking Zydol XL tablets may make you feel more sleepy or increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended that you do not drink alcohol while you are taking Zydol XL tablets. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking these tablets. Pregnancy Do not take these tablets if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. Depending on the dose and duration of treatment with tramadol, slow and shallow breathing (respiratory depression) may occur in the newborn infant. If you use these tablets during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Withdrawal symptoms may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties and sweating. Breast-feeding Do not take these tablets while you are breast-feeding as tramadol passes into breast milk and will affect your baby. Driving and using machines These tablets may cause a number of side effects such as drowsiness, blurred vision and dizziness which could affect your ability to drive or use machinery (see section 4 'Possible side effects' for a full list of side effects). These are usually most noticeable when you first start taking the tablets, or when changing to a higher dose.

  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive if this medicine affects your ability to drive.
  • However you would not be committing an offence if: The medicine has been prescribed to treat a medical or dental problem and; You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and; It was not affecting your ability to drive safely. Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Zydol XL tablets contain lactose These tablets contain lactose which is a form of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking these tablets.

How to take it

Zydol XL tablets Always take these tablets exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Zydol XL, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also section 2). The dosage should be adjusted to the intensity of your pain and your individual pain sensitivity. In general the lowest pain-relieving dose should be taken. Your prescriber should have discussed with you how long the course of tablets will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults and adolescents over 12 years of age The usual starting dose is one 150 mg tablet once a day. However, your doctor will prescribe the dose required to treat your pain. Do not exceed the dose recommended by your doctor. If you find that you are still in pain whilst taking these tablets discuss this with your doctor. Swallow your tablets whole with water. Do not crush, dissolve or chew them. Zydol XL tablets are designed to work properly over 24 hours when swallowed whole. If a tablet is broken, crushed, dissolved or chewed, the entire 24‐hour dose may be absorbed rapidly into your body. This can be dangerous, causing serious problems such as an overdose, which may be fatal. You should take your tablets at the same time every day. For instance, if you take a tablet at 8 o'clock in the morning, you should take your next tablet at 8 o'clock the next morning. Elderly patients In elderly patients (above 75 years) it may take longer for tramadol to leave the body. If this applies to you, your doctor may recommend prolonging the interval between doses. Severe liver or kidney disease (insufficiency)/dialysis patients In patients with severe liver and/or kidney insufficiency it may take longer for tramadol to leave the body. If this applies to you, your doctor may recommend prolonging the interval between doses. Children under 12 years of age Children under 12 years of age should not take the tablets. If you take more Zydol XL tablets than you should or if someone accidentally swallows your tablets Call your doctor or local hospital immediately. People who have taken an overdose may feel very sleepy, sick or dizzy. They may have seizures, fits or convulsions. They may also have breathing difficulties leading to unconsciousness or even death and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining tablets with you. If you forget to take Zydol XL tablets If you remember within 10 hours of the time your tablet was due, take your tablet straight away. Take your next tablet at your normal time. If you are more than 10 hours late, please call your doctor for advice. Do not take a double dose to make up for a forgotten tablet. If you stop taking Zydol XL tablets

Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of these tablets, ask your doctor or pharmacist.

Possible side effects

Like all medicines, these tablets can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reactions are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. These may be signs of a serious allergic reaction. The most serious side effect is a condition where you breathe more slowly or weakly than usual (respiratory depression) and can lead to severe sleepiness and loss of consciousness. This side effect may affect up to 1 in 1,000 people and is more likely to occur when taking certain other medicines (see section 2 'Other medicines and Zydol XL tablets'). Tell your doctor immediately if this happens to you. You may wish to ask your friends, family or caregivers to monitor you for these signs and symptoms. In patients treated with Zydol XL tablets the following other side effects have been reported: Very common (may affect more than 1 in 10 people)

  • feeling sick (this should normally wear off after a few days, however your doctor can prescribe an anti-sickness medicine if it continues to be a problem;
  • dizziness. Common (may affect up to 1 in 10 people)
  • drowsiness (this is most likely when you start taking your tablets or when your dose is increased, but it should wear off after a few days.);
  • vomiting (being sick), dry mouth;
  • excessive sweating. Uncommon (may affect up to 1 in 100 people)
  • headache;
  • a fast heartbeat, feeling your heart beat (palpitations);
  • feeling faint, especially on standing up, low blood pressure, circulation failure;
  • retching;
  • a raised, itchy rash (hives), swelling or puffiness of the skin;
  • constipation;
  • abdominal pain or discomfort;
  • withdrawal symptoms when you stop taking these tablets, known as drug withdrawal syndrome (see section 'Drug Withdrawal'). Rare (may affect up to 1 in 1,000 people)
  • signs of an allergic reaction, including wheeziness, difficulty breathing, swelling of the eyelids, face or lips, rash or itching (see above);

• • • • • • • • • • • • • • • • • •

tingling, pricking or numbness of the skin, impaired judgement, agitation, changes in the way you perceive things around you (sensory disturbance); blurred vision; seeing or hearing things that are not real (hallucinations); nightmares; mood changes, unpleasant or uncomfortable moods or a feeling of extreme happiness; changes in activity levels; confusion; problems with recognition, changes in thinking, memory and behaviour; seizures, fits or convulsions; high blood pressure; shortness of breath, difficulty in breathing or wheezing; worsening of asthma; decreased appetite; diarrhoea; difficulty in passing urine, pain when urinating; muscle weakness; flushing of the skin; slow heartbeat.

Very rare (may affect up to 1 in 10,000 people)

  • a worsening in liver function tests (seen in a blood test). Not known (frequency cannot be estimated from the available data)
  • dependence and addiction (see section 'How do I know if I am addicted?');
  • development of a condition where your breathing stops for short periods whilst you are asleep, known as sleep apnoea;
  • a need to take increasingly higher doses to obtain the same level of pain relief (drug tolerance);
  • serotonin syndrome, that can manifest as mental status changes (e.g. agitation, hallucinations, coma), and other effects, such as fever, increase in heart rate, unstable blood pressure, involuntary twitching, muscular rigidity, lack of coordination and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea) (see section 2 'What you need to know before you take Zydol XL tablets);
  • increased sensitivity to pain;
  • weakness or lack of energy;
  • decrease in blood sugar level;
  • hiccups. Long term use of Zydol XL tablets during pregnancy may cause life-threatening withdrawal symptoms in the newborn. Symptoms to look for in the baby include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, shaking, being sick, diarrhoea and not putting on weight. You may see the remains of the tablets in your faeces. This should not affect how the tablets work. Drug Withdrawal When you stop taking Zydol XL tablets you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted?

If you notice any of the following signs whilst taking Zydol XL, it could be a sign that you have become addicted.

  • You need to take the medicine for longer than advised by your prescriber
  • You feel you need to use more than the recommended dose
  • You are using the medicine for reasons other than prescribed
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again. If you notice any of these signs, it is important you talk to your prescriber. Reporting of side effects If you get any side effects talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Zydol XL tablets Keep these tablets out of the sight and reach of children. Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Do not take these tablets after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Do not store your tablets above 30 ̊C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Zydol XL tablets contain The active ingredient is tramadol hydrochloride. Each tablet contains 400 mg of tramadol hydrochloride. The other ingredients are hydrogenated vegetable oil, talc, magnesium stearate, lactose monohydrate, macrogol, hypromellose (E464), titanium dioxide (E171). What Zydol XL tablets look like and the contents of the pack They are white, film-coated, oval shaped tablets marked T followed by the strength (e.g. 400). The tablets are approximately 19 mm in length. In each box there are 30 tablets. Marketing Authorisation Holder and Manufacturer The tablets are made by Grünenthal GmbH, Zieglerstr. 6, 52078 Aachen, Germany for the marketing authorisation holder Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. Zydol XL 400 mg tablets are supplied by Grünenthal Ltd, TOR Building, Saint Cloud Way, Maidenhead, Berkshire, SL6 8BN, U.K. This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line (free of charge) on: 0800 198 5000 You will need to give details of the product name and reference number. These are as follows: Product name: Zydol XL prolonged release tablets

Reference number: 16950/0092 This leaflet was last revised in January 2025 Zydol® XL tablets are protected by European Patent (UK) No. 0699436 and 0654263. ® ZYDOL is a registered trademark of Grünenthal GmbH. © 2009 – 2025 Napp Pharmaceuticals Limited

Frequently asked questions about Zydol XL 400 mg prolonged-release Tablets

How do I take Zydol XL 400 mg prolonged-release Tablets?

Zydol XL 400 mg prolonged-release Tablets comes as tablet containing 400mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Zydol XL 400 mg prolonged-release Tablets?

The active substance in Zydol XL 400 mg prolonged-release Tablets is tramadol hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Zydol XL 400 mg prolonged-release Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Zydol XL 400 mg prolonged-release Tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Tramadol hydrochloride (43 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment of moderate to severe pain.

These tablets are indicated in adults and adolescents aged 12 years and above.

4.2. Posology and method of administration

Route of administration

Oral use

Posology

The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective correct dose for analgesia should generally be selected. The correct dosage per individual patient is that which controls the pain with no or tolerable side effects for a full 24 hours. Patients transferring from immediate release tramadol preparations should have their total daily dose calculated, and start on the nearest dose in the ZYDOL XL range. It is recommended that patients are slowly titrated to higher doses to minimise transient side effects. The need for continued treatment should be assessed at regular intervals as withdrawal symptoms and dependence have been reported (see section 4.4). A total daily dose of 400 mg should not be exceeded except in special clinical circumstances.

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with tramadol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Adults and children over 12 years:

The usual initial dose is one 150 mg tablet daily. If pain relief is not achieved, the dosage should be titrated upwards until pain relief is achieved.

Geriatric patients:

A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.

Renal insufficiency/dialysis and hepatic impairment:

In patients with renal and/or hepatic insufficiency the elimination of tramadol is delayed. In these patients prolongation of the dosage intervals should be carefully considered according to the patient's requirements.

As tramadol is only removed very slowly by haemodialysis or by haemofiltration, post-dialysis administration to maintain analgesia is not usually necessary.

Paediatric population under 12 years of age:

ZYDOL XL has not been studied in children. The safety and efficacy of ZYDOL XL has not been established and the product should not be used in children.

Method of administration

These tablets should be taken at 24-hourly intervals and must be swallowed whole and not broken, crushed or chewed

Treatment goals and discontinuation

Before initiating treatment with ZYDOL XL, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with tramadol, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids or psychotropic drugs. Tramadol should not be administered to patients who are receiving monoamine oxidase inhibitors or within two weeks of their withdrawal.

Tramadol must not be used for narcotic withdrawal treatment.

4.4. Special warnings and precautions for use

Tolerance and opioid use disorder (abuse and dependence)

Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as tramadol even at therapeutic doses. Repeated use of tramadol can lead to opioid use disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of tramadol may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).

Before initiating treatment with tramadol and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions. Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). If these signs occur, patients should be advised to contact their physician. This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Tolerance

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse and misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Tramadol is not suitable as a substitute in opioid-dependent patients. Although it is an opioid agonist, tramadol cannot suppress morphine withdrawal symptoms.

Tramadol should be used with caution in patients with head injury, intracranial lesions, increased intracranial pressure, severe impairment of hepatic or renal function, in patients in shock or with a reduced level of consciousness of uncertain origin, and with constipation.

The primary risk of opioid excess is respiratory depression.

Care should be taken when treating patients with respiratory depression, or if concomitant CNS depressant drugs (see section 4.5) are being administered, as the possibility of respiratory depression cannot be excluded in these situations. At therapeutic doses respiratory depression has infrequently been reported.

Concomitant use of tramadol and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe tramadol concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Serotonin syndrome

Serotonin syndrome, a potentially life-threatening condition, has been reported in patients receiving tramadol in combination with other serotonergic agents or tramadol alone (see sections 4.5, 4.8 and 4.9). If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose escalations. Symptoms of serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities and/or gastrointestinal symptoms. If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms. Withdrawal of the serotonergic drugs usually brings about a rapid improvement.

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion In patients who present with CSA, consider decreasing the total opioid dosage.

Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit. Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. The risk of convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold (see section 4.5). Tramadol should therefore be used with caution in patients prone to convulsive disorders.

CYP2D6 metabolism

Tramadol is metabolised by the liver enzyme CYP2D6. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect may not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an ultra-rapid metaboliser there is a risk of developing side effects of opioid toxicity even at commonly prescribed doses.

General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarised below:

Population

African/Ethiopian

African American

Asian

Caucasian

Greek

Hungarian

Northern European

Prevalence %

29%

3.4% to 6.5%

1.2% to 2%

3.6% to 6.5%

6.0%

1.9%

1% to 2%

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Adrenal insufficiency

Opioid analgesics may occasionally cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency may include e.g. severe abdominal pain, nausea and vomiting, low blood pressure, extreme fatigue, decreased appetite, and weight loss.

Post-operative use

Prolonged release opioids should not be used for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI).

Paediatric Population

Post-operative use in children

There have been reports in the published literature that tramadol given post-operatively in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnoea, led to rare, but life threatening adverse events. Extreme caution should be exercised when tramadol is administered to children for post-operative pain relief and should be accompanied by close monitoring for symptoms of opioid toxicity including respiratory depression.

Children with compromised respiratory function

Tramadol is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of opioid toxicity.

4.5. Interaction with other medicinal products and other forms of interaction

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Drugs which depress the CNS include but are not limited to: other opioids (including antitussives and substitution therapy), anxiolytics, hypnotics and sedatives (including benzodiazepines), antipsychotics, antidepressants, phenothiazines, barbiturates and alcohol.

The concomitant use of ZYDOL XL with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death.

Tramadol can induce convulsions and increase the potential for selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other seizure threshold-lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions.

Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin syndrome, a potentially life-threatening condition (see sections 4.4 and 4.8).

Simultaneous treatment with carbamazepine may shorten the analgesic effect as a result of a reduction in serum levels of tramadol and its active metabolite.

Co-administration with cimetidine is associated with a small prolongation of the half-life of tramadol, but this is not clinically relevant.

Co-administered ritonavir may increase serum concentrations of tramadol resulting in tramadol toxicity.

Digoxin toxicity has occurred rarely during co-administration of digoxin and tramadol.

Mixed agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine); The analgesic effect of tramadol, which is a pure agonist, may be reduced and a withdrawal syndrome may occur.

There have been isolated reports of interaction with coumarin anticoagulants resulting in an increased INR and so care should be taken when commencing treatment with tramadol in patients on anticoagulants.

The analgesic effect of tramadol is in part mediated by inhibition of the re-uptake of norepinephrine and enhancement of the release of serotonin (5-HT). In studies the pre- or postoperative application of the antiemetic 5-HT3 antagonist ondansetron increased the requirements of tramadol in patients with postoperative pain.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of tramadol in pregnant women. Animal studies have shown reproductive toxicity, but not teratogenic effects (see section 5.3). Tramadol crosses the placental barrier. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available. Tramadol administered before or during birth does not affect uterine contractility.

Breastfeeding

Tramadol is secreted in breast milk and may cause respiratory depression in the infant. Approximately 0.1% of the maternal dose of tramadol is excreted in breast milk. In the immediate post-partum period, for maternal oral daily dosage up to 400 mg, this corresponds to a mean amount of tramadol ingested by breast-fed infants of 3% of the maternal weight-adjusted dosage. For this reason tramadol should not be used during lactation or alternatively, breastfeeding should be discontinued during treatment with tramadol. Discontinuation of breastfeeding is generally not necessary following a single dose of tramadol.

4.7. Effects on ability to drive and use machines

Tramadol may cause drowsiness, blurred vision and dizziness which may be enhanced by alcohol or other CNS depressants. If affected, the patient should not drive or operate machinery.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive.

• Do not drive until you know how the medicine affects you.

• It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').

• This defence applies when:

o

The medicine has been prescribed to treat a medical or dental problem; and

o

You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.

• Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).

Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law.

4.8. Undesirable effects

The following frequency categories form the basis for classification of the undesirable effects:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

Not known (cannot be estimated from the available data)

Very Common

Common

Uncommon

Rare

Very Rare

Not known

Immune system disorders

Hypersensitivity

Anaphylactic and anaphylactoid responses

Metabolism and nutrition disorders

Decreased appetite

Hypoglycaemia

Psychiatric disorders

Hallucinations

Nightmare

Mood altered

Euphoric mood

Dysphoria

Decreased activity

Illusion

Confusional state

Drug dependence (see section 4.4)

Nervous system disorders

Dizziness

Somnolence

Headache

Paraesthesia

Psychomotor hyperactivity

Cognitive disorder

Sensory disturbance

Judgement impaired

Seizure

Sleep apnoea syndrome

Hyperalgesia

Serotonin syndrome

Eye disorders

Blurred vision

Cardiac disorders

Palpitations

Tachycardia

Bradycardia

Vascular disorders

Orthostatic hypotension

Hypotension

Circulatory collapse

Hypertension

Flushing

Respiratory, thoracic and mediastinal disorders

Dyspnoea

Worsening of asthma

Respiratory depression.

Bronchospasm

Wheezing

Hiccups

Gastro-intestinal disorders

Nausea

Vomiting

Dry mouth

Retching

Constipation

Abdominal discomfort

Diarrhoea

Hepatobiliary disorders

Hepatic enzyme increased

Skin and subcutaneous tissue disorders

Hyperhidrosis

Pruritus

Rash

Urticaria

Angioedema

Musculoskeletal and connective tissue disorders

Muscular weakness

Renal and urinary disorders

Micturition disorders

Dysuria

Urinary retention

General disorders and administration site conditions

Drug Withdrawal syndrome which may include:

• agitation;

• anxiety;

• nervousness;

• insomnia;

• hyperkinesia;

• tremor;

• gastrointestinal symptoms.

Asthenia

Drug withdrawal syndrome neonatal

Drug tolerance

Drug dependence

Repeated use of ZYDOL XL can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).

Paediatric population

Neonatal drug withdrawal syndrome may occur in infants born to mothers taking tramadol, however the frequency is unknown (see section 4.6).

As these tablets are made using an insoluble matrix from which the active ingredient is gradually released, the patient may notice the matrix in their faeces.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

Symptoms of overdosage are typical of other opioid analgesics, and include miosis, vomiting, circulatory collapse, sedation and coma, seizures and respiratory depression. Serotonin syndrome has also been reported. In severe cases tramadol overdose may result in a fatal outcome. Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Management

A patent airway must be maintained. The pure opioid antagonists such as naloxone are specific antidotes against symptoms from opioid overdose induced by tramadol, though it will not antagonise tramadol's inhibitory effects on MAO reuptake or serotonin releasing effects. Other supportive measures should be employed as needed. Naloxone should be used to reverse respiratory depression; fits can be controlled with diazepam. In case of oral intake of overdose, consider activated charcoal if the patient presents within one hour of ingestion of tramadol, provided the patient's airway can be protected.

Although it may seem reasonable to assume that later administration of activated charcoal may be beneficial for prolonged-release preparations and drugs that slow gastric emptying, there is no clinical trial evidence to support this.

Tramadol is minimally eliminated from the serum by haemodialysis or haemofiltration. Therefore treatment of acute intoxication with tramadol with haemodialysis or haemofiltration alone is not suitable for detoxification.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • MABRON RETARD 100 mg prescriptionTRAMADOLUM · taken by mouth
  • MABRON RETARD 150 mg prescriptionTRAMADOLUM · taken by mouth
  • MABRON RETARD 200 mg prescriptionTRAMADOLUM · taken by mouth
  • TRAMACALM 50 mg prescriptionTRAMADOLUM · taken by mouth
  • TRAMAL RETARD 100 mg prescriptionTRAMADOLUM · taken by mouth
  • TRAMAL RETARD 150 mg prescriptionTRAMADOLUM · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Tramal Retard 200Tramadoli hydrochloridum · taken by mouth
  • Tramal Retard 100Tramadoli hydrochloridum · taken by mouth
  • Tramal Retard 150Tramadoli hydrochloridum · taken by mouth
  • Tramadol VitabalansTramadoli hydrochloridum · taken by mouth
  • TramundinTramadoli hydrochloridum · taken by mouth
  • Poltram Retard 100Tramadoli hydrochloridum · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Zydol XL 400 mg prolonged-release Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →